Beacon Biosignals is mapping the brain during sleep
Founded by Jake Donoghue PhD ’19 and former MIT researcher Jarrett Revels, the company is creating an AI-driven platform to help diagnose and treat disease.
Founded by Jake Donoghue PhD ’19 and former MIT researcher Jarrett Revels, the company is creating an AI-driven platform to help diagnose and treat disease.
Professor James Collins discusses how collaboration has been central to his research into combining computational predictions with new experimental platforms.
Professors Facundo Batista and Dina Katabi, along with three additional MIT alumni, are honored for their outstanding professional achievement and commitment to service.
Co-founded by an MIT alumnus, Watershed Bio offers researchers who aren’t software engineers a way to run large-scale analyses to accelerate biology.
MIT CSAIL and McMaster researchers used a generative AI model to reveal how a narrow-spectrum antibiotic attacks disease-causing bacteria, speeding up a process that normally takes years.
VaxSeer uses machine learning to predict virus evolution and antigenicity, aiming to make vaccine selection more accurate and less reliant on guesswork.
The team used two different AI approaches to design novel antibiotics, including one that showed promise against MRSA.
A new approach for testing multiple treatment combinations at once could help scientists develop drugs for cancer or genetic disorders.
Trained with a joint understanding of protein and cell behavior, the model could help with diagnosing disease and developing new drugs.
ReviveMed uses AI to gather large-scale data on metabolites — molecules like lipids, cholesterol, and sugar — to match patients with therapeutics.